G M Glenn

Summary

Affiliation: IOMAI Corporation
Country: USA

Publications

  1. pmc Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization
    Mikayel Mkrtichyan
    Department of Immunology, The Institute for Molecular Medicine, Huntington Beach, California, USA
    DNA Cell Biol 27:19-24. 2008
  2. ncbi request reprint Transcutaneous immunization and immunostimulant strategies
    Gregory M Glenn
    IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
    Immunol Allergy Clin North Am 23:787-813. 2003
  3. pmc Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice
    Mimi Guebre-Xabier
    IOMAI Corporation, Gaithersburg, MD 20878, USA
    J Virol 78:7610-8. 2004
  4. ncbi request reprint Mass vaccination: solutions in the skin
    G M Glenn
    IOMAI Corporation, Gaithersburg, MD 20878, USA
    Curr Top Microbiol Immunol 304:247-68. 2006
  5. ncbi request reprint Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study
    Robin McKenzie
    Division of Infectious Diseases, Johns Hopkins University, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, Baltimore, MD 21224, United States
    Vaccine 25:3684-91. 2007
  6. pmc Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum
    Gregory M Glenn
    IOMAI Corporation, 20 Firstfield Road, Gaithersburg, MD 20878, USA
    Infect Immun 75:2163-70. 2007
  7. ncbi request reprint Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch
    Gregory M Glenn
    IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
    Expert Rev Vaccines 6:809-19. 2007
  8. ncbi request reprint Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin
    Gregory M Glenn
    IOMAI Corporation, Gaithersburg, MD 20878, USA
    Expert Rev Vaccines 2:253-67. 2003
  9. ncbi request reprint Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge
    G M Glenn
    Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, DC 20307 5100, USA
    J Immunol 161:3211-4. 1998
  10. pmc Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
    G M Glenn
    Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, D C 20307 5100, USA
    Infect Immun 67:1100-6. 1999

Research Grants

  1. TRANSCUTANEOUS IMMUNIZATION FOR TETANUS BOOSTER
    Gregory Glenn; Fiscal Year: 2003
  2. Formulated Patch for Topical Influenza Vaccine
    Gregory Glenn; Fiscal Year: 2004
  3. Transcutaneous Immunization for an Anthrax Vaccine
    Gregory Glenn; Fiscal Year: 2005

Collaborators

Detail Information

Publications29

  1. pmc Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization
    Mikayel Mkrtichyan
    Department of Immunology, The Institute for Molecular Medicine, Huntington Beach, California, USA
    DNA Cell Biol 27:19-24. 2008
    ....
  2. ncbi request reprint Transcutaneous immunization and immunostimulant strategies
    Gregory M Glenn
    IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
    Immunol Allergy Clin North Am 23:787-813. 2003
    ..During the next 5 years, the challenge will be to conduct a development program that leads to safe and effective vaccination in the context of specific applications...
  3. pmc Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice
    Mimi Guebre-Xabier
    IOMAI Corporation, Gaithersburg, MD 20878, USA
    J Virol 78:7610-8. 2004
    ..Therefore, use of an LT-IS patch could be a new, safe, and simple immunization strategy that may significantly improve the outcome of influenza virus vaccination in the elderly...
  4. ncbi request reprint Mass vaccination: solutions in the skin
    G M Glenn
    IOMAI Corporation, Gaithersburg, MD 20878, USA
    Curr Top Microbiol Immunol 304:247-68. 2006
    ..The combination of the skin immune system, safe use of potent adjuvants and ease of delivery suggests that skin delivery of vaccines can address multiple unmet needs for mass vaccination scenarios...
  5. ncbi request reprint Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study
    Robin McKenzie
    Division of Infectious Diseases, Johns Hopkins University, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, Baltimore, MD 21224, United States
    Vaccine 25:3684-91. 2007
    ..An enterotoxigenic Escherichia coli (ETEC) vaccine could reduce diarrhea among children in developing countries and travelers to these countries. The heat-labile toxin (LT) of ETEC is immunogenic but too toxic for oral or nasal vaccines...
  6. pmc Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum
    Gregory M Glenn
    IOMAI Corporation, 20 Firstfield Road, Gaithersburg, MD 20878, USA
    Infect Immun 75:2163-70. 2007
    ....
  7. ncbi request reprint Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch
    Gregory M Glenn
    IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
    Expert Rev Vaccines 6:809-19. 2007
    ..In this review, we integrate these concepts, update the clinical data and look to the future...
  8. ncbi request reprint Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin
    Gregory M Glenn
    IOMAI Corporation, Gaithersburg, MD 20878, USA
    Expert Rev Vaccines 2:253-67. 2003
    ..These observations have moved into the clinic, highlighting the likelihood that skin delivery of vaccines will play an important future role in vaccine applications...
  9. ncbi request reprint Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge
    G M Glenn
    Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, DC 20307 5100, USA
    J Immunol 161:3211-4. 1998
    ..Thus, clinically relevant immunity against mucosal toxin challenge can be achieved via the transcutaneous route...
  10. pmc Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
    G M Glenn
    Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, D C 20307 5100, USA
    Infect Immun 67:1100-6. 1999
    ..Thus, TCI appears to induce potent, protective immune responses to both systemic and mucosal challenge and offers significant potential practical advantages for vaccine delivery...
  11. ncbi request reprint Transcutaneous immunization: T cell responses and boosting of existing immunity
    S A Hammond
    Walter Reed Army Institute of Research, Department of Membrane Biochemistry, Silver Spring, MD 20910 7500, USA
    Vaccine 19:2701-7. 2001
    ....
  12. ncbi request reprint Principles of transcutaneous immunization using cholera toxin as an adjuvant
    T Scharton-Kersten
    Walter Reed Army Institute of Research, Department of Membrane Biochemistry, 14th and Dahlia Sts NW, Building 40, Rm 3049, Washington, DC 20307, USA
    Vaccine 17:S37-43. 1999
    ..Together these data further our understanding of the principles governing this new platform technology and support its integration into novel and existing human vaccine strategies...
  13. pmc Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells
    Mimi Guebre-Xabier
    IOMAI Corporation, Gaithersburg, Maryland 20878, USA
    J Virol 77:5218-25. 2003
    ....
  14. doi request reprint Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch
    David M Frerichs
    IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
    Vaccine 26:2782-7. 2008
    ..The development of a simple, single-use, disposable device that is well-tolerated and allows disruption to be modulated represents an important step forward in physical penetration enhancement for the skin...
  15. pmc Needle-free skin patch vaccination method for anthrax
    Gary R Matyas
    Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA
    Infect Immun 72:1181-3. 2004
    ..In addition, rPA alone exhibited adjuvant activity for TCI. Forty-six weeks after completion of TCI, 100% protection was observed against lethal anthrax challenge...
  16. ncbi request reprint Transcutaneous immunization of domestic animals: opportunities and challenges
    S A Hammond
    Department of Membrane Biochemistry, Walter Reed Army Institute of Research, RM 2W 124, 503 Robert Grant Avenue, Washington, DC 20307 5100, USA
    Adv Drug Deliv Rev 43:45-55. 2000
    ..The prospect of TCI as a practical and broadly applicable approach to vaccination in veterinary medicine is discussed in the context of these challenges...
  17. ncbi request reprint Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy
    S A Hammond
    IOMAI Corporation, Gaithersburg MD, 20878, USA
    Crit Rev Ther Drug Carrier Syst 18:503-26. 2001
    ..The near-term challenge will be to take this promising insight into successful product development...
  18. pmc Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously
    Fernando Güereña-Burgueño
    Department of Enteric Infections, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910 7500, USA
    Infect Immun 70:1874-80. 2002
    ..The data suggest that an ETEC vaccine for travelers delivered by a patch may be a viable approach worthy of further evaluation...
  19. ncbi request reprint Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch
    Sarah A Frech
    IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
    Vaccine 23:946-50. 2005
    ..The data suggest that an LT IS patch may further enhance influenza vaccine immune responses in the elderly...
  20. doi request reprint Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch
    Gregory M Glenn
    Intercell USA, Inc, 20 Firstfield Road, Gaithersburg, MD 20878, USA
    Vaccine 27:G60-6. 2009
    ..The potent adjuvant, heat labile enterotoxin from E. coli (LT), placed over the immunization site in a patch, is a novel adjuvant strategy for immune enhancement, and was evaluated using an H5N1 injectable vaccine...
  21. pmc Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen
    R L Richards
    Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, D C 20307 5100, USA
    Infect Immun 66:2859-65. 1998
    ..These results demonstrate that encapsulation of a lipid-containing particulate antigen, such as RTS, S, in liposomes containing lipid A can enhance both humoral and cellular immune responses...
  22. ncbi request reprint GM1 binding-deficient exotoxin is a potent noninflammatory broad spectrum intradermal immunoadjuvant
    J Paul Zoeteweij
    IOMAI Corporation, 20 Firstfield Road, Gaithersburg, MD 20878, USA
    J Immunol 177:1197-207. 2006
    ..LT(G33D) is a promising candidate adjuvant for human trials of parenteral vaccines in general and for current i.d. vaccine development in particular...
  23. pmc Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines
    Gregory M Glenn
    Intercell USA, Inc, Gaithersburg, Maryland 20878, USA
    Infect Immun 77:5206-15. 2009
    ..If toxins truly exert barrier-disruptive effects as a key step in pathogenesis, then a return to classic toxin-based vaccine strategies for enteric disease is warranted and can be expected to have unexpectedly broad protective effects...
  24. doi request reprint Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch
    Vladimir G Frolov
    IOMAI Corporation, Gaithersburg, MD 20878, USA
    Influenza Other Respi Viruses 2:53-60. 2008
    ..Because of its effectiveness in vaccine delivery and its superior thermostable characteristics, the dry TIV patch represents a major advance for needle-free influenza vaccination...
  25. ncbi request reprint Induction of protective immunity against lethal anthrax challenge with a patch
    Richard T Kenney
    IOMAI, Gaithersburg, Maryland 20878, USA
    J Infect Dis 190:774-82. 2004
    ..To address critical unmet needs in biodefense against anthrax, we have designed a novel vaccine delivery system using a dry adhesive patch that simplifies administration and improves tolerability of a subunit anthrax vaccine...
  26. ncbi request reprint Dose sparing with intradermal injection of influenza vaccine
    Richard T Kenney
    IOMAI, Gaithersburg, MD 20878, USA
    N Engl J Med 351:2295-301. 2004
    ..The loss of half the U.S. supply of influenza vaccine due to contamination has created a critical shortage. Dose-sparing strategies that use intradermal delivery of vaccines may be one approach to consider...
  27. doi request reprint Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial
    Sarah A Frech
    IOMAI Corporation, Gaithersburg, MD, USA
    Lancet 371:2019-25. 2008
    ..We investigated the rate of diarrhoea attacks, safety, and feasibility of a vaccine containing heat-labile enterotoxin (LT) from ETEC delivered to the skin by patch in travellers to Mexico and Guatemala...
  28. pmc Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1578, USA
    J Clin Invest 113:998-1007. 2004
    ..These results and previous clinical trial results support the observation that TCI is a safe and effective strategy for inducing strong mucosal antibody and CTL responses...
  29. ncbi request reprint Adjuvants: progress, regress and pandemic preparedness
    Gregory M Glenn
    Expert Rev Vaccines 6:651-2. 2007

Research Grants3

  1. TRANSCUTANEOUS IMMUNIZATION FOR TETANUS BOOSTER
    Gregory Glenn; Fiscal Year: 2003
    ..Additionally, the Transcutaneous booster will decrease the risk of needle-sticks and related disease, and reduce personnel and equipment requirements related to tetanus immunization. ..
  2. Formulated Patch for Topical Influenza Vaccine
    Gregory Glenn; Fiscal Year: 2004
    ..Needle-free may also aid in the extension of use of a flu patch into the pediatric population where influenza immunization is now recommended by the ACIP and will be a subsequent goal of this development program. ..
  3. Transcutaneous Immunization for an Anthrax Vaccine
    Gregory Glenn; Fiscal Year: 2005
    ....